Document Detail

Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension.
MedLine Citation:
PMID:  8864793     Owner:  NLM     Status:  MEDLINE    
The endothelial EDRF/NO-mediated relaxing mechanism is impaired in atherosclerotic and in hypertensive arteries. Recently, it was suggested that primary pulmonary hypertension might be another disease in which the endothelial EDRF/NO pathway is disturbed. We tested the hypothesis that intravenous administration of L-arginine (L-ARG), the physiological precursor of EDRF/NO, stimulates the production of NO, subsequently increasing plasma cGMP levels and reducing systemic and/or pulmonary blood pressure, in patients with coronary artery disease (CAD, n = 16) or with primary pulmonary hypertension (PPH, n = 5). L-ARG (30 g, 150 ml, 15 min) or placebo (150 ml NaCl) was infused in CAD patients, and L-ARG was infused in PPH patients during cardiac catheterization. Mean aortic (Pao) and pulmonary (PAPmean) arterial pressures were continuously monitored. Cardiac output (CO, by thermodilution), total peripheral resistance (TPR), and pulmonary vascular resistance (PVR) were measured before and during the infusions. In CAD patients Pao decreased from 87.2 +/- 4.9 to 81.8 +/- 5.1 mmHg during L-ARG (p < 0.05), whereas PAPmean and PVR were unchanged. TPR decreased from 1008.9 +/- 87.9 to 845.0 +/- 81.7 dyne x sec x cm-5 during L-ARG administration (p < 0.01). CO significantly increased during L-ARG (from 7.3 +/- 2.8 to 8.1 +/- 0.9 l/min, p < 0.05). Placebo did not significantly influence any of the hemodynamic parameters. Plasma cGMP (determined by RIA) slightly increased by 12.2 +/- 9.6% during L-ARG, but slightly decreased during placebo (-12.3 +/- 9.2%) (p < 0.05 for L-ARG vs. placebo). In PPH patients, L-ARG induced no significant change in Pao, TPR, and CO, PAPmean was 59.4 +/- 8.5 mmHg at the beginning of the study and was not significantly reduced by L-ARG nor was PVR (basal: 1042.4 +/- 211.4 dyne x sec x cm-5) changed by L-ARG. Plasma cGMP was not significantly affected by L-ARG in these patients. We conclude that L-ARG stimulates NO production and induces vasorelaxation in CAD patients but not in patients with primary pulmonary hypertension.
R H Böger; A Mügge; S M Bode-Böger; D Heinzel; M M Höper; J C Frölich
Related Documents :
6579103 - The developmental effects of prostaglandin d2 on the pulmonary and systemic circulation...
8275153 - A stabilization period of 5 minutes is adequate when measuring pulmonary artery pressur...
2405803 - Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy ...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  34     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  1996 Aug 
Date Detail:
Created Date:  1996-12-12     Completed Date:  1996-12-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  323-8     Citation Subset:  IM    
Institute of Clinical Pharmacology, Medical School, Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arginine / blood,  pharmacology*
Blood Pressure / drug effects*
Coronary Disease / blood,  drug therapy,  physiopathology*
Cyclic GMP / blood
Hypertension, Pulmonary / blood,  drug therapy,  physiopathology*
Infusions, Intravenous
Middle Aged
Pilot Projects
Signal Transduction / drug effects
Vascular Resistance / drug effects*
Reg. No./Substance:
74-79-3/Arginine; 7665-99-8/Cyclic GMP

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tc-99m tetrofosmin myocardial distribution 4 hours post injection.
Next Document:  Zidovudine glucuronidation in human liver: interindividual variability.